Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

Cellistic has launched the Echo-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target ...

a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

Get Instant Summarized Text (Gist) Genetically modified natural killer (NK) cells have shown potential in cancer immunotherapy by overcoming tumor defenses. Using CRISPR/Cas9, researchers ...

Among other functions, the NK cells (Natural Killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...